VERA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VE

Mkt Cap

$2.01B

Volume

840.44K

Next Earnings

November 4th

Loading chart

VE

VERAVera Therapeutics, Inc. Class A Common Stock

VERA

Pay with—

Available Balance0.00

VE

Mkt Cap

$2.06B

Volume

840.44K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William TurnerVera Therapeutics announced that William Turner, current Chief Regulatory Officer, will retire and transition to Strategic Advisor role in Q3 2026. Nancy Boman, M.D., Ph.D., with over 25 years of regulatory affairs experience, will succeed him. The transition follows the recent accelerated FDA approval of TRUTAKNA (atacicept-vymj), the company's first therapy for IgA nephropathy.GlobeNewswire Inc. · Jul 9, 2026

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC FilingRhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics (VERA) during Q1 2026, valued at approximately $18.1 million. The position, which represented 2.0% of the fund's assets in the prior quarter, was fully exited. Despite the sale, Vera Therapeutics stock has surged 81.4% over the past year and outperformed the S&P 500 by 55 percentage points.The Motley Fool · May 26, 2026

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightThe IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.GlobeNewswire Inc. · Apr 29, 2026

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsightThe idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.GlobeNewswire Inc. · Apr 6, 2026

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA DecisionDeerfield Management Company increased its stake in Vera Therapeutics by 418,538 shares during Q4 2025, bringing its total position to $205.58 million (2.6% of fund AUM). Vera's stock has surged 50% over the past year as its lead drug candidate atacicept approaches an FDA decision on July 7, 2026, for treating IgA nephropathy. The company has sufficient cash reserves to fund operations through a potential approval and U.S. launch.The Motley Fool · Mar 13, 2026

Vera Therapeutics Appoints Christopher Hite to Board of DirectorsVera Therapeutics announced the appointment of Christopher Hite, Executive Vice President and Vice Chairman of Royalty Pharma, to its Board of Directors. Hite brings over 25 years of biopharmaceutical industry experience and will serve as an independent board member as the company prepares for the potential launch of atacicept, its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy treatment.GlobeNewswire Inc. · Mar 5, 2026

Vera Therapeutics Announces Pricing of Public Offering of Class A Common StockVera Therapeutics plans to raise approximately $261 million through a public offering of 6,138,108 shares of Class A common stock at $42.50 per share, with underwriters led by J.P. Morgan and Goldman Sachs.GlobeNewswire Inc. · Dec 10, 2025

BK Virus Infection Market Trends, Strategies and Business Prospects 2025-2035 - Lack of FDA-Approved Drugs Spurs Innovation in BK Virus TreatmentThe BK virus infection market is experiencing growth due to increasing organ transplant procedures, lack of FDA-approved drugs, and rising awareness. Innovative therapies and personalized medicine approaches are emerging to address treatment challenges.GlobeNewswire Inc. · Nov 21, 2025

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA NephropathyVera Therapeutics submitted a Biologics License Application to the FDA for atacicept, a potential treatment for IgA Nephropathy, after successful Phase 3 trial results showing significant proteinuria reduction. The drug targets B-cell cytokines and could potentially be approved in 2026.GlobeNewswire Inc. · Nov 7, 2025

Vera (VERA) Q2 Net Loss Widens 127%Vera Therapeutics reported a wider net loss of $76.5 million in Q2 2025, with significant progress on its lead drug atacicept for treating Immunoglobulin A Nephropathy (IgAN). The company showed positive clinical trial results and plans to submit a Biologics License Application to the FDA in Q4 2025.The Motley Fool · Aug 6, 2025

to start trading

VE

VERAVera Therapeutics, Inc. Class A Common Stock

VERA

Pay with—

Available Balance0.00

Your PositionYou don't own any VERA yet.

Related Tickers

Earnings